Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) fell 5.9% on Wednesday . The company traded as low as $2.05 and last traded at $2.09, with a volume of 959,599 shares traded. The stock had previously closed at $2.22.

The stock’s market capitalization is $42.87 million. The firm has a 50 day moving average price of $1.84 and a 200 day moving average price of $1.13.

In related news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $2.74, for a total transaction of $2,855,080.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.